Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques

AIDS

Volumn 26, Issue 3, 2012, Pages 275-284

  Rosario, Maximillian ^a   Borthwick, Nicola ^a,b   Stewart Jones, Guillaume B ^a   Mbewe Mvula, Alice ^a,b   Bridgeman, Anne ^a,b   Colloca, Stefano ^c   Montefiori, David ^d   McMichael, Andrew J ^a   Nicosia, Alfredo ^c,e   Quakkelaar, Esther D ^f   Drijfhout, Jan W ^f   Melief, Cornelis J M ^f   Hanke, Tomáš ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Okairòs Srl ^*  (Italy)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antibodies; conserved regions; HIV vaccine; macaques; prime boost; synthetic long peptides; T cells

Indexed keywords

ADJUVANTED SYNTHETIC LONG PEPTIDE; ANTIBODY; DNA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMIQUIMOD; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONTANIDE; MONTANIDE ISA 51; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELL PROLIFERATION; DNA, VIRAL; ELECTROPORATION; HIV ANTIBODIES; HIV-1; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MACACA MULATTA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84855342224     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834ed9b2     Document Type: Article

References (51)

1. Naswa S, Marfatia YS. Preexposure prophylaxis of HIV. Indian J Sex Transm Dis 2011; 32:1-8.
2. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-255.
3. Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2:e984.
4. Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 2007; 7:1647-1664. (Pubitemid 350161649)
5. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10:300-311.
6. Chiarella P, Fazio VM, Signori E. Application of electroporation in DNA vaccination protocols. Curr Gene Ther 2010; 10: 281-286.
7. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312-317.
8. Hojman P. Basic principles and clinical advancements of muscle electrotransfer. Curr Gene Ther 2010; 10:128-138.
9. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010; 22:264-270.
10. Brave A, Gudmundsdotter L, Sandstrom E, Haller BK, Hallengard D, Maltais AK, et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needlefree intradermal injection and electroporation. Vaccine 2010; 28:8203-8209.
11. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134: 140-147.
12. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-1847.
13. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-187. (Pubitemid 351377994)
14. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351-360. (Pubitemid 351589701)
15. Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, et al. Comparing pooled peptides with intact protein for accessing crosspresentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem 2009; 284:9184-9191.
16. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010; 40:1973-1984.
17. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010; 5:386-390.
18. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 2010; 28:7167-7178.
19. Hanke T. On the growing complexity of HIV-1 vaccines. Future Gene Ther 2010; 4:543-552.
20. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002; 3:627-634. (Pubitemid 34752471)
21. Mo AX, van Lelyveld SF, Craiu A, Rock KL. Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHCclass I-presented peptides. J Immunol 2000; 164:4003-4010. (Pubitemid 30215053)
22. Probst HC, Tschannen K, Gallimore A, Martinic M, Basler M, Dumrese T, et al. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol 2003; 171:5415-5422. (Pubitemid 37432828)
23. van der Most RG, Murali-Krishna K, Lanier JG, Wherry EJ, Puglielli MT, Blattman JN, et al. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 2003; 315:93-102. (Pubitemid 37340053)
24. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51-88. (Pubitemid 29241119)
25. Bridgeman A, Roshorm Y, Lockett LJ, Xu Z-Z, Hopkins R, Shaw J, et al. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 2009; 28:474-483.
26. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24: 4554-4561. (Pubitemid 43776762)
27. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998; 16:439-445. (Pubitemid 28044161)
28. Im E-J, di Gleria K, McMichael AJ, Hanke T. Induction of longlasting multispecific CD8+ T cells by a 4-component DNAMVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 2006; 36:2574-2584. (Pubitemid 44608441)
29. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473-2485. (Pubitemid 47529331)
30. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789. (Pubitemid 43882629)
31. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068. (Pubitemid 35363659)
32. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107:11895-11899.
33. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.Nat Med 2002; 8:379-385. (Pubitemid 34407033)
34. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 2008; 372:1881-1893.
35. Liu Y, McNevin J, Rolland M, Zhao H, Deng W, Maenza J, et al. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis 2009; 200:1825-1833.
36. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998; 187:1647-1657. (Pubitemid 28235106)
37. Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog 2011; 7:e1002041.
38. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173-178. (Pubitemid 43135883)
39. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9:874-880. (Pubitemid 36889929)
40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
41. McElrath MJ. Cellular immune responses induced by HIV vaccines. Prevention from HIV: targeted intervention strategies. Whistler, BC, Canada; 2011.
42. Tomaras GD, Liao HX, Alam SM, Moody MA, Liu P, Yates NL, et al. Analysis of the envelope B cell repertoire in the Thai RV144 efficacy trial. Prevention from HIV: targeted intervention strategies. Whistler, BC, Canada; 2011.
43. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, et al. Long-termsafety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 2003; 21:2933-2947. (Pubitemid 36703204)
44. Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997; 13:1163-1177. (Pubitemid 27408074)
45. Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009; 23:1329-1340.
46. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413.
47. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-1322.
48. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. AIDS clinical trials group 5197: a placebocontrolled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202:705-716.
49. Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, Ranganathan R, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods 2011; 365:27-37.
50. Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 2011; 5:e9852.
51. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30:23-32.